Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Sexual Health Reports
Erschienen in: Current Sexual Health Reports 4/2017

Open Access 19.10.2017 | Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder

verfasst von: Stephanie Both

Erschienen in: Current Sexual Health Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD).

Recent Findings

Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development are testosterone combined with sildenafil or buspiron, bremelanotide, BP101, and nasal testosterone (TBS-2).

Summary

Although pharmacological enhancement of sexual responsiveness may be potentially helpful in the treatment of FSIAD, the observed effects of flibanserin and other new drugs under development seem limited in terms of clinical significance. Given the multifactorial character of FSIAD, it may be important to integrate psychopharmacological treatment with sex therapy for optimal treatment efficacy.
Literatur
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. fifth edition ed. Arlington: American Psychiatric Association; 2013.CrossRef
2.
Baumeister RF, Catanese KR, Vohs KD. Is there a gender difference in strength of sex drive? Theoretical views, conceptual distinctions, and a review of relevant evidence. Personal Soc Psychol Rev. 2001;5:242–73.CrossRef
3.
West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168(13):1441–9.CrossRefPubMed
4.
Witting K, Santtila P, Varjonen M, Jern P, Johansson A, von der PB, et al. Female sexual dysfunction, sexual distress, and compatibility with partner. J Sex Med. 2008;5(11):2587–99.CrossRefPubMed
5.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970–8.CrossRefPubMed
6.
Toates F. An integrative theoretical framework for understanding sexual motivation, arousal, and behavior. J Sex Res. 2009;46(2–3):168–93.CrossRefPubMed
7.
Singer B, Toates FM. Sexual motivation. J Sex Res. 1987;23:481–501.CrossRef
8.
9.
Barlow DH. Causes of sexual dysfunction: the role of anxiety and cognitive interference. J Consult Clin Psychol. 1986;54(2):140–8.CrossRefPubMed
10.
11.
Basson R. The female sexual response: a different model. J Sex Marital Ther. 2000;26(1):51–65.CrossRefPubMed
12.
13.
•• Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs. 2015;29(11):915–33. Gives an extensive and detailed overview of models, neurobiological mechanisms, and approved or investigational drugs for the treatment of HSDD in women. CrossRefPubMed
14.
Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583–8.CrossRefPubMed
15.
Oei N, Rombouts S, Soeter R, van Gerven JM, Both S. Dopamine modulates reward system activity during subconscious processing of sexual stimuli. 2011;
16.
Brom M, Both S, Laan E, Everaerd W, Spinhoven P. The role of conditioning, learning and dopamine in sexual behavior: a narrative review of animal and human studies. Neurosci Biobehav Rev. 2013;38C:38–59.
17.
Pfaus JG, Kippin TE, Centeno S. Conditioning and sexual behavior: a review. Horm Behav. 2001;40(2):291–321.CrossRefPubMed
18.
Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593–9.CrossRefPubMed
19.
Coyle E, Karatzias T, Summers A, Power M. Emotions and emotion regulation in survivors of childhood sexual abuse: the importance of “disgust” in traumatic stress and psychopathology. Eur J Psychotraumatol 2014;5.
20.
Bitzer J, Giraldi A, Pfaus J. Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med. 2013;10(1):36–49.CrossRefPubMed
21.
Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10(7):1807–15.CrossRefPubMed
22.
Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012;9(4):1074–85.CrossRefPubMed
23.
Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793–804.CrossRefPubMed
24.
•• Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62. A critical systematic review and meta-analysis of published and unpublished randomized clinical trials assessing efficacy and safety of flibanserin for the treatment of HSDD in women. CrossRefPubMed
25.
26.
Bancroft J, Graham CA, Janssen E, Sanders SA. The dual control model: current status and future directions. J Sex Res. 2009;46(2):121–42.CrossRefPubMed
27.
• Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, et al. Toward personalized sexual medicine (part 1): integrating the “dual control model” into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. J Sex Med. 2013;10(3):791–809. Decribes the development of drug treatments for HSDD from a theoretical perspective, more specifically the dual control model of sexual response. CrossRefPubMed
28.
van der Made F, Bloemers J, Yassem WE, Kleiverda G, Everaerd W, van Ham D, et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med. 2009;6(3):777–90.CrossRefPubMed
29.
van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 3): testosterone combined with a serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med. 2013;10(3):824–37.CrossRefPubMed
30.
Poels S, Bloemers J, van Rooij K, Goldstein I, Gerritsen J, van Ham D, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med. 2013;10(3):810–23.CrossRefPubMed
31.
Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4(Suppl 4):269–79.CrossRefPubMed
32.
Clayton AH, Althof SE, Kingsberg S, Derogatis LR, Kroll R, Goldstein I, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325–37.
33.
Gorsel H, Laan, Tkachenko NM, Dickstein J, Kreppner W. Pharmacokinetics and pharmacodynamic efficacy of testosterone intranasal gel in women with hypoactive sexual desire disorder and anorgasmia. J Sex Med. 2012;9(3):162–80.
34.
Laan E, Nievaart M, Tkachenko NM, Dickstein J, Kreppner W, Lunsen RHW. Randomized, placebo controlled, five-arm parallel group study to assess efficacy of TBS-2 intranasal gel using vibrotactile stimulation combined with visual sexual stimulation in women with anorgasmia. J Sex Med. 2013;10:165–6.CrossRef
35.
Andreev-Andrievskiy A, Lomonosov M, Popova A, Lagereva E, Clement P, Salimov R, et al. BP101 peptide promotes female sexual receptivity in the rat. J Sex Med. 2017;14(3):336–46.CrossRefPubMed
36.
Mataix-Cols D, DLC F, Monzani B, Rosenfield D, Andersson E, Perez-Vigil A, et al. D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry. 2017;74(5):501–10.CrossRefPubMed
37.
Botreau F, Paolone G, Stewart J. D-cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res. 2006;172(1):173–8.CrossRefPubMed
38.
Paolone G, Botreau F, Stewart J. The facilitative effects of D-cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. Psychopharmacology. 2009;202(1–3):403–9.CrossRefPubMed
39.
• Brom M, Laan E, Everaerd W, Spinhoven P, Trimbos B, Both S. D-cycloserine reduces context specificity of sexual extinction learning. Neurobiol Learn Mem. 2015;125:202–10. The first study that showed facilitating effects of d-cycloserine, a learning enhancing drug, on sexual associative learning. CrossRefPubMed
40.
Both S, Weijmar Schultz WC, Laan E. Treating women’s sexual desire and arousal problems. In: Peterson ZD, editor. The Wiley handbook of sex therapy. Sussex: John Wiley & Sons; 2017. p. 11–31.
41.
• Conaglen HM, Conaglen JV. Integrating sexual partners into pharmacological sex therapy. In: Peterson ZD, editor. The Wiley handbook of sex therapy. Sussex: John Wiley & Sons; 2017. p. 453–67. Describes the importance and ways to integrate pharmacological treatment of sexual dysfunction with sex therapy for the couple. CrossRef
Metadaten
Titel
Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder
verfasst von
Stephanie Both
Publikationsdatum
19.10.2017
Verlag
Springer US
Erschienen in
Current Sexual Health Reports / Ausgabe 4/2017
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-017-0124-3

Weitere Artikel der Ausgabe 4/2017

Current Sexual Health Reports 4/2017 Zur Ausgabe

Medical Comorbidities (M Miner, S Parish and A Goldstein, Section Editors)

Testosterone and Physical Function

Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Persistent Genital Arousal Disorder: Current Conceptualizations and Etiologic Mechanisms

Male and Female Surgical Interventions (A Burnett and C Carson, Section Editors)

Surgical Reconstruction After Penile Cancer Surgery

Male and Female Surgical Interventions (A Burnett and C Carson, Section Editors)

An Update on the Management of the Short Penis: Results from a Systematic Review

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation

Female Sexual Dysfunction and Disorders (M Chivers and C Pukall, Section Editors)

Brain Imaging of Human Sexual Response: Recent Developments and Future Directions

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen